Protagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 Shares

by · The Markets Daily

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) Director William Waddill sold 9,000 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $99.64, for a total transaction of $896,760.00. Following the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $779,683. The trade was a 53.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Stock Down 4.7%

Shares of PTGX stock traded down $4.64 during trading hours on Monday, hitting $94.92. 816,649 shares of the company’s stock traded hands, compared to its average volume of 735,036. The stock’s 50 day simple moving average is $101.73 and its 200 day simple moving average is $92.11. The stock has a market cap of $6.10 billion, a PE ratio of -52.44 and a beta of 1.86. Protagonist Therapeutics, Inc. has a 12 month low of $47.53 and a 12 month high of $107.84.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The business had revenue of $56.37 million during the quarter, compared to the consensus estimate of $11.70 million. As a group, equities research analysts expect that Protagonist Therapeutics, Inc. will post 3.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

PTGX has been the subject of a number of analyst reports. Truist Financial lifted their target price on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a research note on Tuesday, April 14th. Citizens Jmp lifted their target price on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Barclays lifted their target price on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. TD Cowen lifted their target price on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, Leerink Partners lifted their target price on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $115.21.

View Our Latest Analysis on Protagonist Therapeutics

Institutional Investors Weigh In On Protagonist Therapeutics

A number of large investors have recently bought and sold shares of PTGX. Janus Henderson Group PLC grew its holdings in Protagonist Therapeutics by 140.7% in the fourth quarter. Janus Henderson Group PLC now owns 2,649,981 shares of the company’s stock worth $231,355,000 after purchasing an additional 1,549,160 shares during the period. Wellington Management Group LLP grew its holdings in Protagonist Therapeutics by 66.2% in the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after purchasing an additional 1,262,977 shares during the period. Vanguard Group Inc. grew its holdings in shares of Protagonist Therapeutics by 27.2% during the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock valued at $472,832,000 after buying an additional 1,156,461 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Protagonist Therapeutics during the third quarter valued at about $72,114,000. Finally, Commodore Capital LP acquired a new position in shares of Protagonist Therapeutics during the second quarter valued at about $59,415,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.

Read More